John C WIlliams

John C. Williams supports the Defense Health Agency’s mission by managing critical procurement activities focused on medical equipment maintenance, surgical instrument manufacturing, and pharmaceutical supply chain resilience. While his official title is not disclosed, his procurement portfolio reflects deep engagement with technical and operational healthcare infrastructure, ensuring that military medical facilities maintain readiness through reliable, high-performance equipment and services. He routinely oversees contracts under FAR Part 13 and Part 15 procedures, balancing urgent operational needs with long-term sustainment planning across global DOD healthcare sites. Williams maintains consistent working relationships with specialized vendors including Dependable On-Site Scan & Shred, Inc. for secure medical records handling, Hanith Bioscience, LLC for advanced diagnostic solutions, Livion Technology, LLC for clinical workflow optimization, I-2-I Solutions, Inc. for IT-enabled health data systems, and Draeger Inc. for critical care and anesthesia equipment. These partnerships reflect a preference for niche providers with proven expertise in military medical environments, emphasizing reliability, compliance, and rapid response capabilities. His contracting approach prioritizes small business participation, with 40% of acquisitions structured as total small business set-asides under FAR 19.5, demonstrating a strong commitment to socioeconomic programs. While no specific set-aside categories like 8(a) or HUBZone dominate his portfolio, the consistent use of small business set-asides signals intentional support for agile, innovative vendors capable of meeting DHA’s dynamic operational demands. Williams’ procurement focus centers on NAICS 811310 for industrial equipment maintenance, 339112 for surgical instrument manufacturing, and 325412 for pharmaceutical preparation, underscoring expertise in clinical hardware sustainment and pharmaceutical logistics. His work ensures the uninterrupted availability of mission-critical medical technologies, aligning acquisition strategy with DHA’s priorities in modernizing clinical workflows and securing resilient health supply chains.